Business Context and Reporting Period
Company: Immunocore Holdings Plc
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: November 7, 2023
Reporting Period: This filing incorporates by reference the Unaudited Condensed Consolidated Interim Financial Statements and Management's Discussion and Analysis for the three and nine months ended September 30, 2023. It also includes a press release dated November 7, 2023.
Key Financial Metrics
The provided text serves as a cover document and does not contain specific numerical data for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the incorporated exhibits (Exhibit 99.1 and 99.2) which are not included in the input text.
- Revenue: Not provided in text.
- Profit/Loss: Not provided in text.
- Cash Flow: Not provided in text.
- Debt and Liquidity: Not provided in text.
Material Changes
The filing text does not provide specific details on material changes versus prior periods. It references the Management's Discussion and Analysis (Exhibit 99.2) for a discussion of financial condition and results of operations.
Guidance, Outlook, and Risks
Forward-Looking Statements: The filing contains a cautionary note regarding forward-looking statements. These statements involve risks and uncertainties, and actual results may differ materially from expectations. The company undertakes no obligation to update these statements except as required by law.
Risks: Investors are directed to the "Risk Factors" and "Management's Discussion and Analysis" sections in the company's SEC filings for a discussion of factors that may cause actual results to differ from forward-looking statements.
Exhibit Status: Exhibit 99.3 (Press Release) is furnished but not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 for the specific financial figures (revenue, net loss, cash position) for the three and nine months ended September 30, 2023.
- Read Exhibit 99.2 to understand the reasons behind any material changes in financial performance compared to prior periods.
- Examine Exhibit 99.3 (Press Release) for any specific operational updates or clinical trial announcements made on November 7, 2023.
- Consult the most recent Form 20-F for a comprehensive list of risk factors applicable to the company.